tenofovir disoproxil emtricitabine viatris
viatris limited - emtricitabine 200mg; ; tenofovir disoproxil maleate 300mg equivalent to tenofovir disoproxil 245 mg; emtricitabine 200mg; tenofovir disoproxil maleate 300mg equivalent to tenofovir disoproxil 245 mg - film coated tablet - 200 mg/300 mg - active: emtricitabine 200mg tenofovir disoproxil maleate 300mg equivalent to tenofovir disoproxil 245 mg excipient: colloidal silicon dioxide hyprolose iron oxide red lactose monohydrate magnesium stearate microcrystalline cellulose opadry green 31k510010 active: emtricitabine 200mg tenofovir disoproxil maleate 300mg equivalent to tenofovir disoproxil 245 mg excipient: colloidal silicon dioxide hyprolose iron oxide red lactose monohydrate magnesium stearate microcrystalline cellulose opadry green 32k510087 - treatment of hiv-1 infection tenofovir disoproxil emtricitabine viatris is indicated for the treatment of hiv infected adults over the age of 18 years, in combination with other antiretroviral agents.
fenofibrate viatris fenofibrate 48 mg tablet blister pack
viatris pty ltd - fenofibrate, quantity: 48 mg - tablet - excipient ingredients: microcrystalline cellulose; sodium lauryl sulfate; lactose monohydrate; sucrose; hypromellose; docusate sodium; magnesium stearate; colloidal anhydrous silica; crospovidone; titanium dioxide; sunset yellow fcf aluminium lake; purified talc; xanthan gum; polyvinyl alcohol; quinoline yellow aluminium lake; lecithin; indigo carmine aluminium lake - fenofibrate viatris is indicated as an adjunct to diet in the treatment of: - hypercholesterolaemia; - types ii, iii, iv and v dyslipidaemia; - dyslipidaemia associated with type 2 diabetes.
fenofibrate viatris fenofibrate 145 mg tablet blister pack
viatris pty ltd - fenofibrate, quantity: 145 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium lauryl sulfate; crospovidone; hypromellose; magnesium stearate; lactose monohydrate; docusate sodium; microcrystalline cellulose; sucrose; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - fenofibrate viatris is indicated as an adjunct to diet in the treatment of: - hypercholesterolaemia; - types ii, iii, iv and v dyslipidaemia; - dyslipidaemia associated with type 2 diabetes.
oxycodone viatris oxycodone hydrochloride 5 mg tablet blister pack
viatris pty ltd - oxycodone hydrochloride, quantity: 5 mg - tablet, uncoated - excipient ingredients: lactose; microcrystalline cellulose; stearic acid - oxycodone viatris is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.
atazanavir viatris
viatris limited - atazanavir sulfate 170.85mg equivalent to atazanavir 150mg; atazanavir sulfate 170.85mg equivalent to atazanavir 150mg - capsule - 150 mg - active: atazanavir sulfate 170.85mg equivalent to atazanavir 150mg excipient: crospovidone gelatin iron oxide red lactose monohydrate magnesium stearate patent blue v purified water tekprint black sw-9008 titanium dioxide active: atazanavir sulfate 170.85mg equivalent to atazanavir 150mg excipient: brilliant blue fcf crospovidone erythrosine gelatin iron oxide yellow lactose monohydrate magnesium stearate purified water titanium dioxide - atazanavir viatris is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents, in adult patients and in paediatric patients 6 to 18 years of age. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies.
atazanavir viatris
viatris limited - atazanavir sulfate 227.8mg equivalent to atazanavir 200mg; atazanavir sulfate 227.8mg equivalent to atazanavir 200mg - capsule - 200 mg - active: atazanavir sulfate 227.8mg equivalent to atazanavir 200mg excipient: brilliant blue fcf crospovidone erythrosine gelatin lactose monohydrate magnesium stearate purified water titanium dioxide active: atazanavir sulfate 227.8mg equivalent to atazanavir 200mg excipient: crospovidone gelatin indigo carmine iron oxide yellow lactose monohydrate magnesium stearate patent blue v purified water tekprint black sw-9008 titanium dioxide - atazanavir viatris is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents, in adult patients and in paediatric patients 6 to 18 years of age. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies.
atazanavir viatris
viatris limited - atazanavir sulfate 341.7mg equivalent to atazanavir 300mg; atazanavir sulfate 341.7mg equivalent to atazanavir 300mg - capsule - 300 mg - active: atazanavir sulfate 341.7mg equivalent to atazanavir 300mg excipient: brilliant blue fcf crospovidone erythrosine gelatin iron oxide red iron oxide yellow lactose monohydrate magnesium stearate purified water titanium dioxide active: atazanavir sulfate 341.7mg equivalent to atazanavir 300mg excipient: crospovidone gelatin iron oxide red iron oxide yellow lactose monohydrate magnesium stearate patent blue v purified water tekprint black sw-9008 titanium dioxide - atazanavir viatris is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents, in adult patients and in paediatric patients 6 to 18 years of age. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies.
capecitabine viatris
viatris limited - capecitabine 150mg; ; - film coated tablet - 150 mg - active: capecitabine 150mg excipient: croscarmellose sodium hypromellose iron oxide red iron oxide yellow lactose magnesium stearate microcrystalline cellulose purified talc purified water titanium dioxide - capecitabine viatris tablets in combination with docetaxel is indicated for the treatment of patients with locally-advanced or metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. capecitabine viatris tablets as monotherapy is indicated for the treatment of patients with locally-advanced or metastatic breast cancer after failure of both a taxane-containing and anthracycline-containing chemotherapy or in whom taxane-containing and anthracycline-containing therapy are not indicated.
capecitabine viatris
viatris limited - capecitabine 500mg; ; - film coated tablet - 500 mg - active: capecitabine 500mg excipient: croscarmellose sodium hypromellose iron oxide red iron oxide yellow lactose magnesium stearate microcrystalline cellulose purified talc purified water titanium dioxide - capecitabine viatris tablets in combination with docetaxel is indicated for the treatment of patients with locally-advanced or metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. capecitabine viatris tablets as monotherapy is indicated for the treatment of patients with locally-advanced or metastatic breast cancer after failure of both a taxane-containing and anthracycline-containing chemotherapy or in whom taxane-containing and anthracycline-containing therapy are not indicated.
meloxicam viatris meloxicam 7.5 mg tablet blister pack
helix pharmaceuticals pty ltd - meloxicam, quantity: 7.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; povidone; magnesium stearate; sodium citrate dihydrate; colloidal anhydrous silica; crospovidone; microcrystalline cellulose - meloxicam is indicated for symptomatic treatment of osteoarthritis and rheumatoid arthritis.